Your session is about to expire
← Back to Search
Alpha-1 Blocker
Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction
Phase 4
Waitlist Available
Led By Stephen Nakada, MD
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* Patients with unilateral ureteral stent placement for urolithiasis
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 42-48 hours post-stent insertion
Awards & highlights
All Individual Drugs Already Approved
Pivotal Trial
Approved for 5 Other Conditions
No Placebo-Only Group
Drug Has Already Been Approved
Summary
The purpose of this study is to determine whether combination therapy with Tolterodine ER and Tamsulosin is more effective than monotherapy with tamsulosin alone in reducing stent symptoms. The second purpose is to determine if people have less stent discomfort if they take these medications starting 2 weeks before the stent is placed The investigators hope to show that the addition of Tolterodine ER to Tamsulosin will provide added benefits in reducing stent symptoms in patients who have had unilateral placement of a ureteral stent.
Eligible Conditions
- Ureteral Obstruction
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 42-48 hours post-stent insertion
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~42-48 hours post-stent insertion
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Ureteral Stent Symptom Questionnaire Score
Ureteral Stent Symptom Questionnaire Score 5-7 Days Post-stent Insertion
Ureteral Stent Symptom Questionnaire Score Up to 24 Hours After Stent Removal
+1 moreAwards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Trial Design
4Treatment groups
Experimental Treatment
Active Control
Group I: Tamsulosin plus Tolterodine ER 7-day treatmentExperimental Treatment2 Interventions
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity.
Group II: Tamsulosin plus Tolterodine ER 21-day treatmentExperimental Treatment2 Interventions
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity.
Group III: Tamsulosin plus placebo 21-day treamtnetActive Control1 Intervention
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Group IV: Tamsulosin plus placebo 7-day treatmentActive Control1 Intervention
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tolterodine
FDA approved
Tamsulosin
FDA approved
Find a Location
Who is running the clinical trial?
University of Wisconsin, MadisonLead Sponsor
1,237 Previous Clinical Trials
3,200,818 Total Patients Enrolled
Stephen Nakada, MDPrincipal InvestigatorUniveristy of Wisconsin
3 Previous Clinical Trials
190 Total Patients Enrolled